Financial Snapshot

Revenue
$163.5M
TTM
Gross Margin
Net Earnings
-$59.51M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
476.25%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$261.9M
Q3 2024
Cash
Q3 2024
P/E
-7.838
Nov 29, 2024 EST
Free Cash Flow
-$61.61M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Revenue $166.8M $206.0M $12.36M $9.539M $20.79M $15.75M $13.00M $20.38M $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -19.03% 1566.79% 29.56% -54.12% 31.97% 21.18% -36.21%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Revenue $166.8M $206.0M $12.36M $9.539M $20.79M $15.75M $13.00M $20.38M $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Selling, General & Admin $52.87M $46.07M $41.45M $23.22M $12.66M $20.58M $7.570M $3.450M $4.990M $5.840M $3.220M $680.0K $2.080M
YoY Change 14.76% 11.15% 78.51% 83.41% -38.48% 171.86% 119.42% -30.86% -14.55% 81.37% 373.53% -67.31%
% of Gross Profit
Research & Development $192.1M $147.8M $173.8M $57.85M $33.64M $16.98M $15.92M $17.93M $13.46M $25.11M $7.070M $820.0K $1.820M
YoY Change 30.04% -14.97% 200.38% 71.96% 98.09% 6.67% -11.21% 33.21% -46.4% 255.16% 762.2% -54.95%
% of Gross Profit
Depreciation & Amortization $2.957M $1.527M $1.193M $880.0K $680.0K $580.0K $410.0K $290.0K $50.00K $30.00K $10.00K $10.00K $10.00K
YoY Change 93.65% 28.0% 35.57% 29.41% 17.24% 41.46% 41.38% 480.0% 66.67% 200.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $245.0M $193.8M $215.2M $81.06M $46.30M $37.56M $23.49M $21.38M $19.70M $33.08M $10.29M $1.500M $3.910M
YoY Change 26.41% -9.94% 165.49% 75.07% 23.26% 59.91% 9.87% 8.53% -40.45% 221.48% 586.0% -61.64%
Operating Profit -$78.21M $12.18M -$202.9M -$71.52M -$25.51M -$21.81M
YoY Change -742.24% -106.0% 183.61% 180.34% 16.97%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Interest Expense $16.36M -$1.533M -$822.0K -$620.0K -$480.0K $30.00K -$60.00K -$290.0K $300.0K $230.0K -$200.0K -$80.00K -$20.00K
YoY Change -1167.32% 86.5% 32.58% 29.17% -1700.0% -150.0% -79.31% -196.67% 30.43% -215.0% 150.0% 300.0%
% of Operating Profit -12.59%
Other Income/Expense, Net $16.59M -$420.0K -$1.921M -$361.0K -$446.0K $328.0K -$350.0K -$250.0K
YoY Change -4050.24% -78.14% 432.13% -19.06% -235.98% -193.71% 40.0%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Pretax Income -$27.89M $10.64M -$203.7M -$72.15M -$25.92M -$21.60M -$10.90M -$1.540M -$19.40M -$32.85M -$10.49M -$1.580M -$3.930M
YoY Change -362.03% -105.23% 182.3% 178.33% 19.99% 98.2% 607.79% -92.06% -40.94% 213.16% 563.92% -59.8%
Income Tax $1.835M $1.295M $0.00 $40.00K $50.00K -$20.00K $60.00K $0.00 $0.00
% Of Pretax Income 12.17%
Net Earnings -$29.73M $9.349M -$203.7M -$72.15M -$25.99M -$21.79M -$10.90M -$1.570M -$19.45M -$32.83M -$10.55M -$1.580M -$3.930M
YoY Change -417.95% -104.59% 182.3% 177.59% 19.31% 99.86% 594.27% -91.93% -40.76% 211.18% 567.72% -59.8%
Net Earnings / Revenue -17.82% 4.54% -1647.98% -756.35% -125.02% -138.29% -83.85% -7.7%
Basic Earnings Per Share -$1.12 $0.35 -$7.74
Diluted Earnings Per Share -$1.12 $0.35 -$7.739M -$3.552M -$2.153M -$2.164M -$3.528M -$773.4K -$6.294M -$16.84M -$7.276M -$1.423M -$3.509M

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Cash & Short-Term Investments $292.0M $391.9M $370.5M $462.9M $71.40M $36.70M $48.60M $8.300M $50.70M $21.70M $50.10M $100.0K $600.0K
YoY Change -25.49% 5.77% -19.96% 548.32% 94.55% -24.49% 485.54% -83.63% 133.64% -56.69% 50000.0% -83.33%
Cash & Equivalents $292.0M $391.9M $370.5M $462.9M $71.40M $36.70M $25.00M $8.300M $16.70M $2.200M $22.10M $100.0K $100.0K
Short-Term Investments $0.00 $23.60M $0.00 $34.00M $19.50M $28.00M $0.00 $500.0K
Other Short-Term Assets $62.52M $8.686M $5.102M $2.800M $800.0K $600.0K $1.800M $300.0K $1.600M $300.0K $100.0K $100.0K $0.00
YoY Change 619.79% 70.25% 82.21% 250.0% 33.33% -66.67% 500.0% -81.25% 433.33% 200.0% 0.0%
Inventory
Prepaid Expenses
Receivables $32.06M $2.764M $3.367M $2.100M $2.200M $4.500M $500.0K $3.600M
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $386.6M $403.3M $379.0M $467.8M $74.30M $41.80M $50.90M $12.30M $52.30M $22.10M $50.20M $200.0K $700.0K
YoY Change -4.15% 6.43% -18.99% 529.61% 77.75% -17.88% 313.82% -76.48% 136.65% -55.98% 25000.0% -71.43%
Property, Plant & Equipment $40.93M $44.96M $11.26M $8.600M $7.500M $2.000M $1.000M $1.300M $200.0K $100.0K $0.00 $0.00 $0.00
YoY Change -8.97% 299.25% 30.94% 14.67% 275.0% 100.0% -23.08% 550.0% 100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $515.0K $300.0K $300.0K $19.00M $0.00 $500.0K
YoY Change -100.0% 0.0% -100.0%
Other Assets $1.885M $2.094M $2.077M $100.0K $100.0K $100.0K $100.0K $100.0K $100.0K $100.0K $100.0K $0.00 $0.00
YoY Change -9.98% 0.82% 1977.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Total Long-Term Assets $42.81M $47.05M $13.85M $8.700M $7.800M $2.400M $1.100M $1.400M $19.40M $200.0K $100.0K $0.00 $500.0K
YoY Change -9.02% 239.67% 59.23% 11.54% 225.0% 118.18% -21.43% -92.78% 9600.0% 100.0% -100.0%
Total Assets $429.4M $450.4M $392.8M $476.5M $82.10M $44.20M $52.00M $13.70M $71.70M $22.30M $50.30M $200.0K $1.200M
YoY Change
Accounts Payable $5.279M $7.449M $10.06M $10.80M $5.800M $2.400M $1.800M $3.400M $100.0K $300.0K $0.00 $0.00 $100.0K
YoY Change -29.13% -25.94% -6.87% 86.21% 141.67% 33.33% -47.06% 3300.0% -66.67% -100.0%
Accrued Expenses $31.88M $30.23M $23.52M $19.40M $4.400M $3.900M $1.800M $400.0K $2.200M $2.000M $1.500M $100.0K $100.0K
YoY Change 5.45% 28.52% 21.25% 340.91% 12.82% 116.67% 350.0% -81.82% 10.0% 33.33% 1400.0% 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $100.0K $0.00 $0.00 $0.00 $700.0K $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due $0.00 $60.66M $22.47M $1.300M
YoY Change -100.0% 169.89% 1628.77%
Total Short-Term Liabilities $78.86M $127.0M $99.54M $49.50M $21.30M $12.60M $11.00M $8.700M $2.400M $2.400M $1.600M $800.0K $200.0K
YoY Change -37.9% 27.57% 101.08% 132.39% 69.05% 14.55% 26.44% 262.5% 0.0% 50.0% 100.0% 300.0%
Long-Term Debt $0.00 $0.00 $40.63M $13.80M $15.00M $9.900M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -100.0% 194.44% -8.0% 51.52%
Other Long-Term Liabilities $68.90M $53.09M $24.43M $16.50M $20.00M $8.100M $7.200M $3.400M
YoY Change 29.78% 117.29% 48.08% -17.5% 146.91% 12.5% 111.76%
Total Long-Term Liabilities $68.90M $53.09M $65.07M $30.30M $35.00M $18.00M $7.200M $3.400M $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change 29.78% -18.4% 114.74% -13.43% 94.44% 150.0% 111.76%
Total Liabilities $147.8M $180.1M $164.6M $79.90M $56.40M $30.60M $18.20M $12.20M $2.400M $2.400M $1.600M $800.0K $200.0K
YoY Change -17.95% 9.4% 106.01% 41.67% 84.31% 68.13% 49.18% 408.33% 0.0% 50.0% 100.0% 300.0%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
Basic Shares Outstanding 26.63M 26.45M 26.32M
Diluted Shares Outstanding 26.63M 27.09M 26.32M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $466.44 Million

About Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The company is headquartered in San Diego, California and currently employs 180 full-time employees. The company went IPO on 2013-05-22. The firm is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. The company is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.

Industry: Pharmaceutical Preparations Peers: Invivyd, Inc. ALBIREO PHARMA, INC. Humacyte, Inc. Anika Therapeutics, Inc. Celularity Inc EAGLE PHARMACEUTICALS, INC. Karyopharm Therapeutics Inc. MeiraGTx Holdings plc Monte Rosa Therapeutics, Inc.